Recruiting

Nellcor™ Device

Sponsor:

Medtronic - MITG

Code:

NCT07234279

Conditions

Oxygen Saturation

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Study Details

Brief summary:

To examine pulse rate and blood oxygen saturation accuracy of the Nellcor™ Investigational Device during non-motion and walking motion conditions in a diverse patient population through non-invasive means

Conditions

Oxygen Saturation

Study ID

NCT07234279

Start date

Aug 11, 2026

Status verified date

Oct, 2026

Completion date

Oct 30, 2026

Anticipated

Primary completion date

Oct 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Male or female participants ≥18 years of age, and <75 years of age.
  • Participant is able to participate for the duration of the study
  • Participant is willing to sign an informed consent form (ICF)
  • Participant weighs > 40kg
  • Participants must be a non-smoker or not have smoked within 36 hours prior to the study

Exclusion Criteria:

  • Participant self-reported prior injury or trauma to fingers or hands, which in the opinion of the investigator, may change blood flow or vascular supply and affect the ability to test sensors
  • Physiologic abnormalities that prevent proper application of pulse oximetry sensor
  • Severe contact allergies that cause a reaction to standard adhesive materials such as those found in medical sensors and electrodes
  • Individuals of childbearing potential who are self-reported as pregnant, or who are self-reported as trying to get pregnant
  • Morbid obesity (defined as BMI > 39.5)
  • Weight > 136 kg
  • Participants who self-report problems of unsteadiness or imbalance issues and/or who are unable to walk on a treadmill without holding onto the handrails
  • Participant self-reported known heart or cardiovascular conditions such as:
  • Uncontrolled hypertension (Systolic pressure ≥ 140mmHg or Diastolic pressure > 90mmHg on 3 consecutive readings day of screening)
  • Heart arrhythmias other than sinus arrhythmia (Self-reported and/or as identified on ECG day of screening).
  • History of heart attack, blocked artery, history of myocardial ischemia, angina, myocardial infarction, congestive heart failure, cardiomyopathy, stroke, transient ischemic attack, or carotid artery disease
  • Participants with self-reported clotting disorders, such as:
  • History of bleeding disorders or personal history of prolonged bleeding from injury
  • History of blood clots
  • Hemophilia
  • Current use of prescription blood thinner
  • Participants with other self-reported, known health conditions, such as:
  • Diabetes
  • Thyroid disease
  • Kidney disease / chronic renal impairment
  • History of seizures (except childhood febrile seizures), epilepsy, or unexplained syncope
  • Recent history of frequent migraine headaches, as determined medically relevant by the PI
  • History of head injury, as determined medically relevant by the PI
  • Cancer / chemotherapy
  • Sickle cell disease
  • History of hospital admission or a surgical procedure in the 60 days prior to study enrollment (self-reported)
  • Participants with any contraindications to protocol specific repositioning techniques
  • Unwillingness or inability to remove colored nail polish from test digit(s)
  • Participants who have self-reported health conditions beyond what is captured in the prior exclusion criteria, which in the opinion of the Investigator and/or Clinical Staff would classify the participant as medically unsuitable

Study Design

Enrollment

30 participants

Anticipated

Interventions and Outcome Measures

Arms

Healthy Volunteers

All subjects who meet the inclusion criteria and none of the exclusion criteria will be enrolled into the test group and will participate in data collection with use of the Nellcor™ Investigational device.

Primary outcome measure

  • Accuracy of the investigational device SpO2 as compared to the reference device SpO2 [ Time Frame: From enrollment to study exit, 1.5 hours ]
  • Accuracy of the investigational device pulse rate as compared to the reference device pulse rate. [ Time Frame: From enrollment to study exit, 1.5 hours ]

Central Contacts and Locations

Central contacts

Hannah Bowman

720-930-1695Hannah.bowman@medtronic.com

Ami Stuart

ami.stuart@medtronic.com

Locations

Clinical Physiology Lab

Recruiting

Denver, Colorado, United States, 80217

Contacts

Clinical Research Manager

303-570-1721roger.martin-pressman@medtronic.com

More Information

Sponsor

Medtronic - MITG

Last update posted

Oct 19, 2026

Last verified

Oct, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-20. This information was provided to ClinicalTrials.gov by Medtronic - MITG on 2026-10-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.